We are live on
!
Find out more
OCA
Octagon Capital Advisors Portfolio holdings
AUM
$904M
1-Year Est. Return
737.04%
This Fund
S&P 500
This Quarter
Est. Return
+42.42%
1 Year Est. Return
+737.04%
3 Year Est. Return
+2,554.78%
5 Year Est. Return
+4,333.84%
10 Year Est. Return
–
AUM
$625M
AUM Growth
-$25.9M
(-4%)
Cap. Flow
-$169M
Cap. Flow
% of AUM
-27.04%
Top 10 Holdings %
Top 10 Hldgs %
76.62%
Holding
51
New
11
Increased
5
Reduced
12
Closed
18
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Structure Therapeutics
GPCR
|
+$23.7M |
| 2 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$10.6M |
| 3 |
Immunovant
IMVT
|
+$10.1M |
| 4 |
ALPN
Alpine Immune Sciences Inc
ALPN
|
+$6.83M |
| 5 |
RAPT
RAPT Therapeutics
RAPT
|
+$4.52M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$28.5M |
| 2 |
ETNB
89bio
ETNB
|
+$18.8M |
| 3 |
Roivant Sciences
ROIV
|
+$18.3M |
| 4 |
APLS
Apellis Pharmaceuticals
APLS
|
+$16.4M |
| 5 |
Amylyx Pharmaceuticals
AMLX
|
+$12.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
APLS
1
DELISTED
Apellis Pharmaceuticals
APLS
| $168M | 26.88% |
2,806,980
-323,020
| -10% | -$16.4M |
|
|
CBAY
2
DELISTED
Cymabay Therapeutics
CBAY
| $63.2M | 10.1% |
2,673,750
-400,000
| -13% | -$7.12M |
|
|
VRNA
3
DELISTED
Verona Pharma
VRNA
| $47.1M | 7.54% |
2,369,000
| – | – |
|
4
Insmed
INSM
$23.2B
| $39.8M | 6.37% |
1,284,000
| – | – |
|
5
Arcus Biosciences
RCUS
$3.57B
| $35.7M | 5.71% |
1,868,000
-100,000
| -5% | -$1.6M |
|
6
BridgeBio Pharma
BBIO
$16.5B
| $28.5M | 4.57% |
706,800
-264,839
| -27% | -$7.95M |
|
7
Celldex Therapeutics
CLDX
$2.77B
| $28.1M | 4.49% |
707,526
-52,372
| -7% | -$1.54M |
|
|
8
Roivant Sciences
ROIV
$25.2B
| $28M | 4.48% |
2,494,000
-1,873,000
| -43% | -$18.3M |
|
|
ALPN
9
DELISTED
Alpine Immune Sciences Inc
ALPN
| $23.7M | 3.79% |
1,241,300
+491,300
| +66% | +$6.83M |
|
|
10
Structure Therapeutics
GPCR
$3.49B
| $16.9M | 2.7% |
+414,000
| New | +$23.7M |
|
|
CNTA
11
DELISTED
Centessa Pharmaceuticals
CNTA
| $16.4M | 2.62% |
2,060,100
+1,584,500
| +333% | +$10.6M |
|
12
AN2 Therapeutics
ANTX
$177M
| $13.6M | 2.18% |
664,575
-203,000
| -23% | -$3.4M |
|
13
Viridian Therapeutics
VRDN
$2.13B
| $13.5M | 2.16% |
620,000
-447,143
| -42% | -$7.06M |
|
|
14
Immunovant
IMVT
$8.09B
| $11.5M | 1.84% |
+273,289
| New | +$10.1M |
|
15
Dyne Therapeutics
DYN
$4.04B
| $10.5M | 1.69% |
792,945
+100,000
| +14% | +$977K |
|
16
Cytokinetics
CYTK
$11B
| $9.68M | 1.55% |
+116,000
| New | +$4.2M |
|
17
Annexon
ANNX
$855M
| $9.31M | 1.49% |
2,050,000
| – | – |
|
|
JBIO
18
Jade Biosciences
JBIO
$1.22B
| $9.14M | 1.46% |
11,534
-2,677
| -19% | -$1.36M |
|
19
Gossamer Bio
GOSS
$66.5M
| $8.38M | 1.34% |
9,187,883
+1,000,000
| +12% | +$739K |
|
|
RAPT
20
DELISTED
RAPT Therapeutics
RAPT
| $7.26M | 1.16% |
+36,500
| New | +$4.52M |
|
|
CBIO
21
Crescent Biopharma
CBIO
$602M
| $7.08M | 1.13% |
30,000
| – | – |
|
|
GRCL
22
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
| $5.99M | 0.96% |
+596,611
| New | +$2.71M |
|
23
Dianthus Therapeutics
DNTH
$5.68B
| $5.76M | 0.92% |
554,000
+74,000
| +15% | +$817K |
|
|
OKUR
24
OnKure Therapeutics
OKUR
$166M
| $3.6M | 0.58% |
225,000
-2,987
| -1% | -$186K |
|
25
Jasper Therapeutics
JSPR
$22.9M
| $3.53M | 0.56% |
446,811
| – | – |
|
Similar funds
AIC
AOWM
SWM
EI
PIP
PSCM
EWM
PC
Octagon Capital Advisors's Q4 2023 Portfolio in Review
As of Q4 2023, Octagon Capital Advisors held 51 positions worth $625M, down 4% from $651M the previous quarter. Its ten largest holdings account for 77% of the portfolio.
Octagon Capital Advisors withdrew a net $169M in Q4 2023, closing 18 positions and reducing 12 holdings. Its most notable exit was Mirati Therapeutics, Inc. Common Stock, an estimated $28.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 87% a quarter earlier.
Against the trend, Octagon Capital Advisors opened a new position in Structure Therapeutics worth $16.9M.
- Octagon Capital Advisors's largest Q4 2023 buy was Structure Therapeutics: 414,000 shares worth $16.9M.
- Octagon Capital Advisors added most to Centessa Pharmaceuticals in Q4 2023, an estimated $10.6M increase.
- Octagon Capital Advisors's biggest Q4 2023 reduction was Roivant Sciences, cutting an estimated $18.3M.
- Octagon Capital Advisors fully exited Mirati Therapeutics, Inc. Common Stock in Q4 2023, selling an estimated $28.5M.
- Octagon Capital Advisors's ten largest holdings make up 77% of its $625M portfolio in Q4 2023.
- Octagon Capital Advisors opened 11 new positions and closed 18 in Q4 2023.
- Octagon Capital Advisors's portfolio value fell 4% quarter-over-quarter to $625M.
Based on Octagon Capital Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.